Cytopia is developing CYT997, a new anti-cancer agent that disrupts tumour blood vessels. CYT997 is currently being investigated in Phase II clinical trials in a variety of cancers.
Read more
Myeloproliferative disorders (MPDs) are debilitating, and potentially fatal, diseases of blood cell production. Cytopia is developing JAK2 inhibitors for the treatment of myeloproliferative disease, cancer and pulmonary hypertension (PAH). The company's lead drug, CYT387, is expected to enter Ph I clinical trials late 2009.
Read more
Cytopia has partnered its JAK3 program with Novartis, one of the world's largest pharmaceutical companies, for the development of new anti-rejection drugs for transplantation, as well as for treatment of auto-immune diseases. JAK3 is a key enzyme necessary for the function of white blood cells which mediate transplant rejection.
Read more
Quick Links
Link Market Services Ltd provide the share registry services to all Cytopia shareholders CIBC Mellon Trust Company
CIBC Mellon Trust Company (Toronto, CA) provide the Investor services to all YM BioSciences shareholders
Cytopia has a strong and growing intellectual property platform Intellectual Property / Patents
Cytopia has a strong and growing intellectual property platform
Archive of Cytopia's annual reports Annual Reports
Archive of Cytopia's annual reports

The merger between Cytopia and YM BioSciences has now formally been implemented pursuant to the Scheme of Arrangement conducted by Cytopia. With effect 1 February, 2010, Cytopia has requested that its shares be delisted and the company becomes a wholly-owned subsidiary of YM BioSciences Inc. All Cytopia shareholders registered at 25 January 2010 will shortly be issued with new shares in YM BioSciences Inc. For detailed information on YM Shares please click here

The current Cytopia website will remain active, and will update shareholders on all activities within the two companies. Clear links to the YM BioSciences website will also be provided. Cytopia will continue to update all interested parties registered on the mailing list including Cytopia shareholders who have previously registered .

For more information on YM BioSciences please visit www.ymbiosciences.com .

To read the latest YM BioSciences News click here

.

1 February 2010 Announcement from YM BioSciences Inc.
YM BioSciences completes merger with Cytopia

1 February 2010
Implementation of Merger with YM BioSciences
18 January 2010
Suspension of Trading
18 January 2010
Scheme of Arrangement - Lodgement of Court Orders
15 January 2010
Court Approval of Scheme Arrangement
12 January 2010
Results of Scheme Meeting
12 January 2010
Results of 2009 Annual General Meeting
12 January 2010
Scheme Meeting - Chairman's Address

To subscribe or unsubscribe to Cytopia email Announcements, please email cytopia@cytopia.com.au with the word 'subscribe' or 'unsubscribe' in the subject line
Copyright © 2009 by Cytopia Ltd. All rights reserved. | Site use and privacy policy